BioTelemetry (BEAT) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results
October 29, 2020 4:05 PM EDTMALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020.
Quarter Highlights
Recognized quarterly total revenue of $114.7 millionReached 3.0% year-over-year quarterly revenue growth, despite the impact of COVID-19Reported quarterly GAAP net income of $6.7 million, or 5.9% of total revenueRealized quarterly adjusted EBITDA of $30.6 million, or 26.7% of total revenueAcquired Remote Patient Monitoring... More